NEXGEL INC
NXGLNASDAQTrading Snapshot
- Day Range
- $0.16 – $0.16
- 52-Week Range
- $0.16 – $2.89
- Volume
- $5.91B
- Avg Volume
- $4.25B
- Shares Outstanding
- 8.5M
- Next Earnings
- Nov 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $11M
- Last Q Revenue
- $4M
- P/E Ratio
- -0.2
- P/S Ratio
- 0.1x
- EPS (TTM)
- $-0.69
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +7.6%
Why Investors Own NXGL
- ✓High-growth profile — revenue up +15.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 35% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
NEXGEL INC
NXGL
StockOtter · stockotter.spaceAbout NEXGEL INC
NEXGEL, Inc. is a company that develops and produces advanced hydrogels and gels. These materials are characterized by their significant water content, aqueous polymer composition, and electron beam cross-linking technology. NEXGEL's diverse product range serves crucial applications across several sectors, including wound care management, medical diagnostic tools, transdermal drug delivery systems, and cosmetic formulations. The company was founded in 1997 and operated under the name AquaMed Technologies, Inc. until it rebranded as NEXGEL, Inc. in November 2019. Its headquarters are located in Langhorne, Pennsylvania.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript
NEXGEL, Inc. (NXGL) Discusses Strategic Platform Reorganization and Refocus on Medical Device and Biomedical Innovation Transcript
NEXGEL Announces Dial-In Details for Investor Update Call
LANGHORNE, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians t
NEXGEL Announces Date for Investor Update Call
LANGHORNE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a company with a patient centric medical technology sales and marketing team working closely with clinicians t
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
LANGHORNE, Pa. , Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a series of leadership, governance and strategic initiatives designed to strengthen operational
NEXGEL Reports Second Quarter 2026 Financial Results
LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-wate